Cargando…
Adjuvant treatment with dexamethasone plus anti-C5 antibodies improves outcome of experimental pneumococcal meningitis: a randomized controlled trial
BACKGROUND: We compared adjunctive treatment with placebo, dexamethasone, anti-C5 antibodies, and the combination of dexamethasone plus anti-C5 antibodies in experimental pneumococcal meningitis. METHODS: In this prospective, investigator-blinded, randomized trial, 96 mice were infected intracistern...
Autores principales: | Kasanmoentalib, E. Soemirien, Valls Seron, Mercedes, Morgan, B. Paul, Brouwer, Matthijs C., van de Beek, Diederik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536776/ https://www.ncbi.nlm.nih.gov/pubmed/26272468 http://dx.doi.org/10.1186/s12974-015-0372-y |
Ejemplares similares
-
Mannose-binding lectin-associated serine protease 2 (MASP-2) contributes to poor disease outcome in humans and mice with pneumococcal meningitis
por: Kasanmoentalib, E. Soemirien, et al.
Publicado: (2017) -
Erratum to: Mannose-binding lectin-associated serine protease 2 (MASP-2) contributes to poor disease outcome in humans and mice with pneumococcal meningitis
por: Kasanmoentalib, E. Soemirien, et al.
Publicado: (2017) -
Exome Array Analysis of Susceptibility to Pneumococcal Meningitis
por: Kloek, Anne T., et al.
Publicado: (2016) -
Complement factor H contributes to mortality in humans and mice with bacterial meningitis
por: Kasanmoentalib, E. Soemirien, et al.
Publicado: (2019) -
Variation of 46 Innate Immune Genes Evaluated for their Contribution in Pneumococcal Meningitis Susceptibility and Outcome
por: Ferwerda, Bart, et al.
Publicado: (2016)